Using AMG900 to Treat Breast Cancer

November 12, 2013
Richard S. Finn, MD

Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the aurora kinase inhibitor AMG900.

Clinical Pearls

  • AMG900 is a small molecule inhibitor of aurora kinases, which are proteins that are involved in maintaining DNA integrity and controlling DNA replication
  • AMG900 has been evaluated in breast cancer models to try to determine which group of patients will benefit
  • Results of an AMG900 trial showed that patients with p53 mutation may have a potential benefit with the agent
  • p53 mutations are common throughout all the molecular subtypes of breast cancer but triple-negative breast cancer (TNBC) shows a higher frequency of these mutations
  • This early preclinical work suggests that p53 mutations may act as a biomarker for selecting patients who will benefit from AMG900
  • AMG900 is now in a phase I study that includes patients with TNBC and a biomarker component will be included in the study to help researchers get a better understanding of how the drug is working